14-Day Prulifloxacin Treatment of Acute Uncomplicated cystitis in Women with Recurrent Urinary Tract Infections: A Prospective, Open-Label, Pilot Trial With 6-Month Follow-Up

REFERENCES

• Hooton TM, Scholes D, Hughers JP, et al. A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med 1996; 335 (7): 468–474.
   PubMed Web of Science ®Google Scholar
• Hooton TM. Pathogenesis of urinary tract infections: an update. J Antimicrob Chemother 2000; 46 (Suppl 1): 1-7; dis-cussion 63-65.
   Google Scholar
• Grabe M, Bishop MC, Bjerklund-Johansen TE, Sotto M, cek M, Lobel B, Naber KG, Palou J, Tenke P. Guidelines on the Management of Urinary and Male Genital Tract Infections. http : //www. uroweb . o rg /nc/prof essi onal-r esour ces/guide-lines/online/
   Google Scholar
• Ernst EJ, Ernst ME, Hoehns JD, Bergus GR. Women's quality of life is decreased by acute cystitis and antibiotic adverse effects associated with treatment. Health Qual Life Outcomes 2005; 3: 45.
   PubMedGoogle Scholar
• Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of un-complicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin In-fect Dis 1999; 29 (4): 745–758.
   PubMed Web of Science ®Google Scholar
• Miller LG, Tang AW. Treatment of uncomplicated urinary tract infections in an era of increasing antimicrobial resistance. Mayo Clin Proc 2004; 79 (8): 1048–1053.
   PubMed Web of Science ®Google Scholar
• Schaeffer AJ. The expanding role of fluoroquinolones. Dis Mon 2003; 49 (2): 129–147.
   PubMed Web of Science ®Google Scholar
• Keam SJ, Perry CM. Prulifloxacin. Drugs 2004; 64 (19): 2221-2234; discussion 2235-2236.
   Google Scholar
• Matera MG. Pharmacologic characteristics of prulifloxacin. Pulm Pharmacol Ther 2006; 19 (Suppl 1): 20–29.
   PubMed Web of Science ®Google Scholar
• Prats G, Rossi V, Salvatori E, Mirelis B. Prulifloxacin: a new antibacterial fluoroquinolone. Expert Rev Anti Infect Ther 2006; 4 (1): 27–41.
   PubMedGoogle Scholar
• Rubin RH, Shapiro ED, Andriole VT, Davis RJ, Stamm WE. Evaluation of new anti-infective drugs for the treatment of urinary tract infection. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15 (Suppl 1): S216–227.
   PubMed Web of Science ®Google Scholar
• Ludwig M, Hoyme U, Weidner W. Recurrent urinary tract infection in women. Long-term antibiotic prophylaxis. Urologe A 2006; 45 (4): 436–442.
   Google Scholar
• Gupta K, Hooton TM, Roberts PL, Stamm WE. Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women. Arch Intern Med 2007; 167 (20): 2207–2212.
   PubMedGoogle Scholar
• Milo G, Katchman EA, Paul M, Christiaens T, Baerheim A, Leibovici L. Duration of antibacterial treatment for uncompli- cated urinary tract infection in women. Cochrane Database Syst Rev 2005; (2): CD004682.
   Google Scholar
• Motrich RD, Cuffini C, Mackern Oberti JP, Maccioni M, Rivero VE. Chlamydia trachomatis occurrence and its impact on sperm quality in chronic prostatitis patients. J Infect 2006; 53 (3): 175–183.
   PubMed Web of Science ®Google Scholar
• Mazzoli S, Cai T, Rupealta V, Gavazzi A, Castricchi Pagliai R, Mondaini N, et al. Interleukin 8 and anti-chlamydia tra-chomatis mucosal IgA as urogenital immunologic markers in Patients with C. trachomatis prostatic infection. Eur Urol 2007; 51 (5): 1385-1393.
   Google Scholar
• Pannekoek Y, Westenberg SM, de Vries J. PCR assess-ment of Chlamydia trachomatis infection of semen specimens processed for artificial insemination. J Clin Microbiol 2000; 38 (10): 3763–3767.
   PubMed Web of Science ®Google Scholar
• Hooton TM, Scholes D, Gupta K, Stapleton AE, Roberts PL, Stamm WE. Amoxicillin-clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women: a randomized trial. JAMA 2005; 293 (8): 949–955.
   PubMed Web of Science ®Google Scholar
• Kaplan RM, Bush JW, Berry CC. Health status: types of validity and the index of well-being. Health Serv Res 1976; 11 (4): 478–507.
   PubMed Web of Science ®Google Scholar
• Clayson D, Wild D, Doll H, Keating K, Gondek K. Vali-dation of a patient-administered questionnaire to measure the severity and bothersomeness of lower urinary tract symptoms in uncomplicated urinary tract infection (UTI): the UTI Symptom Assessment questionnaire. BJU Int 2005; 96 (3): 350–359.
   PubMed Web of Science ®Google Scholar
• Taur Y, Smith MA: Adherence to the Infectious Diseases Society of America Guidelines in the treatment of uncomplicated urinary tract infections. Clin Infect Dis 2007; 44 (6): 769–774.
   PubMed Web of Science ®Google Scholar
• Giannarini G, Mogorovich A, Valent F, Morelli G, De Maria M, Manassero F, et al. Prulifloxacin versus levofloxacin in the treatment of chronic bacterial prostatitis: a prospective, ran-domized, double-blind trial. J Chemother 2007; 19 (3): 304–308.
   PubMed Web of Science ®Google Scholar
• Matsumoto T. Urinary tract infections in the elderly. Curr Urol Rep 2001; 2 (4): 330–333.
   PubMedGoogle Scholar
• Norinder BS, Norrby R, Palmgren AC, Hollenberg S, Eriksson U, Nord CE. Microflora changes with norfloxacin and pivmecillinam in women with recurrent urinary tract infection. Antimicrob Agents Chemother 2006; 50 (4): 1528–1530.
   PubMed Web of Science ®Google Scholar
• Stapleton A. Novel approaches to prevention of urinary tract infections. Infect Dis Clin North Am 2003; 17 (2): 457–471.
   PubMed Web of Science ®Google Scholar
• Stapleton A, Stamm WE. Prevention of urinary tract in-fection. Infect Dis Clin North Am 1997; 11 (3): 719–733.
   PubMed Web of Science ®Google Scholar
• Giannarini G, Tascini C, Selli C. Prulifloxacin: clinical studies of a broad-spectrum quinolone agent. Future Microbiol. 2009; 4: 13–24.
   PubMed Web of Science ®Google Scholar
• Gorlero F, Lorenzi P, Rosignoli MT, Picollo R, Ruggieri A, Baratte S, et al. Penetration of prulifloxacin into gynaecolog-ical tissues after single and repeated oral administrations. Drugs R D 2007; 8 (6): 373–381.
   PubMedGoogle Scholar
• Mikuniya T, Kato Y, Ida T, Maebashi K, Monden K, Kariyama R, et al. Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model. J Infect Chemother 2007; 13 (5): 285–290.
   PubMedGoogle Scholar
• Fadda G, Nicoletti G, Schito GC, Tempera G. Antimi-crobial susceptibility patterns of contemporary pathogens from uncomplicated urinary tract infections isolated in a multicenter Italian survey: possible impact on guidelines. J Chemother 2005; 17 (3): 251–257.
   PubMed Web of Science ®Google Scholar
• Carmignani G, De Rose AF, Olivieri L, Salvatori E, Rosig-noli MT, Dionisio P. Prulifloxacin versus ciprofloxacin in the treatment of adults with complicated urinary tract infections. Urol Int 2005; 74 (4): 326–331.
   PubMed Web of Science ®Google Scholar
• Mazzoli S. Conventional bacteriology in prostatitis Patients: microbiological bias, problems and epidemiology on 1686 microbial isolates. Arch hal Urol Androl. 2007; 79 (2): 71–5.
   PubMedGoogle Scholar